T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Quatromoni, Jon G ^a   Wang, Yue ^a   Vo, Dan D ^a   Morris, Lilah F ^a   Jazirehi, Ali R ^a   McBride, William ^a   Chatila, Talal ^a   Koya, Richard C ^a   Economou, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROTEIN PMEL 1; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE CELL THERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; MELANOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84862275097     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-127     Document Type: Article

References (32)

1. Dudley ME, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16(24):6122-6131. 10.1158/1078-0432.CCR-10-1297, 2978753, 20668005.
2. Goff SL, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother 2010, 33(8):840-847. 10.1097/CJI.0b013e3181f05b91, 20842052.
3. Rosenberg SA, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8(4):299-308. 10.1038/nrc2355, 2553205, 18354418.
4. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007, 13(18 Pt 1):5256-5261.
5. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007, 13(18 Pt 1):5262-5270.
6. Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007, 121(10):2119-2124. 10.1002/ijc.23113, 17849476.
7. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007, 7(6):443-453. 10.1038/nri2095, 17525753.
8. Fahlen L, et al. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 2005, 201(5):737-746. 10.1084/jem.20040685, 2212836, 15753207.
9. Carrier Y, et al. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol 2007, 178(1):172-178.
10. Chen ML, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 2005, 102(2):419-424. 10.1073/pnas.0408197102, 544311, 15623559.
11. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25(3):455-471. 10.1016/j.immuni.2006.07.011, 16973386.
12. Bollard CM, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99(9):3179-3187. 10.1182/blood.V99.9.3179, 11964281.
13. Foster AE, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008, 31(5):500-505. 10.1097/CJI.0b013e318177092b, 2745436, 18463534.
14. Lacuesta K, et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother 2006, 29(3):250-260. 10.1097/01.cji.0000192104.24583.ca, 16699368.
15. Wang L, et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells. Clin Cancer Res 2010, 16(1):164-173. 10.1158/1078-0432.CCR-09-1758, 20028741.
16. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001, 7(10):1118-1122. 10.1038/nm1001-1118, 11590434.
17. Overwijk WW, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198(4):569-580. 10.1084/jem.20030590, 2194177, 12925674.
18. Wieser R, et al. Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993, 13(12):7239-7247. 364794, 8246946.
19. Koya RC, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A 2010, 107(32):14286-14291. 10.1073/pnas.1008300107, 2922609, 20624956.
20. Ribas A, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997, 57(14):2865-2869.
21. Ribas A, et al. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol 2004, 172(8):4762-4769.
22. Craft N, et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005, 175(3):1983-1990.
23. Vo DD, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69(22):8693-8699. 10.1158/0008-5472.CAN-09-1456, 2779578, 19861533.
24. Wrzesinski C, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010, 33(1):1-7. 10.1097/CJI.0b013e3181b88ffc, 3247626, 19952961.
25. Kano MR, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A 2007, 104(9):3460-3465. 10.1073/pnas.0611660104, 1800736, 17307870.
26. Penafuerte C, Galipeau J. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother 2008, 57(8):1197-1206. 10.1007/s00262-008-0453-1, 18214474.
27. Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008, 21(2):123-132. 10.1111/j.1755-148X.2008.00450.x, 18426405.
28. Tian F, et al. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice. Cancer Lett 2008, 271(2):333-341. 10.1016/j.canlet.2008.06.025, 18675506.
29. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002, 195(11):1499-1505. 10.1084/jem.20012076, 2193549, 12045248.
30. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26(5):579-591. 10.1016/j.immuni.2007.03.014, 17481928.
31. Horwitz DA, et al. Critical role of IL-2 and TGF-beta in generation, function and stabilization of Foxp3 + CD4+ Treg. Eur J Immunol 2008, 38(4):912-915. 10.1002/eji.200738109, 18395858.
32. Harlin H, et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55(10):1185-1197. 10.1007/s00262-005-0118-2, 16468035.